Clinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile
December 11, 2017 10:00 ET
|
eFFECTOR Therapeutics
Preclinical Data Shows Potential of eFT226 in B-cell Malignancies Data to be presented at the ASH 59th Annual Meeting and Exposition SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- eFFECTOR...
eFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological Effects
November 10, 2017 10:00 ET
|
EFFECTOR Therapeutics
SAN DIEGO, Nov. 10, 2017 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced a poster...
The Jackson Laboratory and Seven Bridges Collaborate to Build Centralized Data Platform to Advance Cancer Research
October 17, 2017 07:58 ET
|
The Jackson Labratory
FARMINGTON, Conn., and BOSTON, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- The Jackson Laboratory (JAX), a nonprofit biomedical research institution, and Seven Bridges, the leading biomedical data...
eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer
October 04, 2017 10:00 ET
|
EFFECTOR Therapeutics
SAN DIEGO, Oct. 04, 2017 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has...
Surgical Oncologists and Oncology Health Care Professionals Come Together in Seattle to Discuss Groundbreaking Research and Advancements in the Surgical Treatment of Cancer
February 15, 2017 11:21 ET
|
Society of Surgical Oncology
ROSEMONT, Ill., Feb. 15, 2017 (GLOBE NEWSWIRE) -- The Society of Surgical Oncology (SSO) will host the 70th SSO Annual Cancer Symposium March 15-18, 2017 at the Washington State Convention Center in...
Commence Bio to Present at 2016 Cell & Gene Meeting on the Mesa
September 28, 2016 12:37 ET
|
Commence Bio
SPARKS, MD--(Marketwired - September 28, 2016) - Commence Bio, Inc., a biotechnology company focused on developing breakthrough immunotherapies using its proprietary STaRT™ platform, announced today...
Commence Bio Receives 1st Patent for MSC1: A New Cancer Immunotherapy Platform
June 20, 2016 18:45 ET
|
Commence Bio
SPARKS, MD --(Marketwired - June 20, 2016) - Commence Bio, Inc. (Commence) today announced the issuance of a patent covering the company's STaRT 41™ technology utilized for producing MSC1 cells....
New Potential Lung Cancer Biomarkers Identified
April 19, 2016 08:00 ET
|
Protea Biosciences, Inc.
NEW ORLEANS, April 19, 2016 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc., (OTCQB:PRGB) announced the use of its proprietary bioanalytical technology to achieve the molecular profiling of...
Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors
December 16, 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today further progress on developing Ampligen® (rintatolimod)...
RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON(R) From WILEX AG
June 30, 2014 06:00 ET
|
RedHill Biopharma Ltd.
RedHill expands its late clinical-stage gastrointestinal-focused pipeline with MESUPRON®, an oncology drug targeting gastrointestinal and other solid tumor cancers licensed from Wilex...